Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia

Journal of Infectious Diseases

Volumn 209, Issue 1, 2014, Pages 120-129

  Maude, Richard J ^a,b   Silamut, Kamolrat ^a   Plewes, Katherine ^a   Charunwatthana, Prakaykaew ^a   Ho, May ^c   Abul Faiz, M ^a,d,e   Rahman, Ridwanur ^f   Hossain, Md Amir ^g   Hassan, Mahtab U ^g   Bin Yunus, Emran ^d,e   Hoque, Gofranul ^g   Islam, Faridul ^g   Ghose, Aniruddha ^g   Hanson, Josh ^a   Schlatter, Joel ^h   Lacey, Rachel ⁱ   Eastaugh, Alison ⁱ   Tarning, Joel ^a,b   Lee, Sue J ^a,b   White, Nicholas J ^a,b   Chotivanich, Kesinee ^a   Day, Nicholas P J ^a,b   Dondorp, Arjen M ^a,b   more..

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CALGARY   (Canada)

^d Centre for Specialized Care and Research   (Bangladesh)

^e Dev Care Foundation   (Bangladesh)

^f Shaheed Shwarwardhy Medical College   (Bangladesh)

^g CHITTAGONG MEDICAL COLLEGE HOSPITAL   (Bangladesh)

^h HÔPITAL JEAN VERDIER   (France)

ⁱ WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

artesunate; falciparum; levamisole; malaria; sequestration; severe

Indexed keywords

ARTESUNATE; LACTIC ACID; LEVAMISOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BANGLADESH; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; FEMALE; HOSPITAL ADMISSION; HUMAN; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MAXIMUM PLASMA CONCENTRATION; MICROVASCULARIZATION; PARASITE CLEARANCE; PARASITE EXAMINATION; PARASITEMIA; PATIENT REFERRAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ARTESUNATE; FALCIPARUM; LEVAMISOLE; MALARIA; SEQUESTRATION; SEVERE;

ADULT; ANTIMALARIALS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LACTIC ACID; LEVAMISOLE; MALARIA, FALCIPARUM; MALE; MICROVESSELS; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; REGIONAL BLOOD FLOW;

EID: 84891363760     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit410     Document Type: Article

References (48)

1. World Health Organization. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000; 94(suppl 1):S1-90.
2. Silamut K, Phu NH, Whitty C, et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol 1999; 155:395-410.
3. Silamut K, White NJ. Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg 1993; 87:436-43.
4. Magowan C, Wollish W, Anderson L, Leech J. Cytoadherence by Plasmodium falciparum-infected erythrocytes is correlated with the expression of a family of variable proteins on infected erythrocytes. J Exp Med 1988; 168:1307-20.
5. Barnwell JW, Asch AS, Nachman RL, Yamaya M, Aikawa M, Ingravallo P. A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparuminfected erythrocytes. J Clin Invest 1989; 84:765-72.
6. Ockenhouse CF, Tandon NN, Magowan C, Jamieson GA, Chulay JD. Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. Science 1989; 243:1469-71.
7. Berendt AR, Simmons DL, Tansey J, Newbold CI, Marsh K. Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for Plasmodium falciparum. Nature 1989; 341:57-9.
8. Ockenhouse CF, Tegoshi T, Maeno Y, et al. Human vascular endothelial cell adhesion receptors for Plasmodium falciparum-infected erythrocytes: roles for endothelial leukocyte adhesion molecule 1 and vascular cell adhesion molecule 1. J Exp Med 1992; 176:1183-9.
9. Yipp BG, Anand S, Schollaardt T, Patel KD, Looareesuwan S, Ho M. Synergism of multiple adhesion molecules in mediating cytoadherence of Plasmodium falciparum-infected erythrocytes to microvascular endothelial cells under flow. Blood 2000; 96:2292-8.
10. Ho M, Hickey MJ, Murray AG, Andonegui G, Kubes P. Visualization of Plasmodium falciparum-endothelium interactions in human microvasculature: mimicry of leukocyte recruitment. J Exp Med 2000; 192: 1205-11.
11. Ho M, Schollaardt T, Niu X, Looareesuwan S, Patel KD, Kubes P. Characterization of Plasmodium falciparum-infected erythrocyte and P-selectin interaction under flow conditions. Blood 1998; 91:4803-9.
12. Udomsangpetch R, Reinhardt PH, Schollaardt T, Elliott JF, Kubes P, Ho M. Promiscuity of clinical Plasmodium falciparum isolates for multiple adhesion molecules under flow conditions. J Immunol 1997; 158:4358-64.
13. Yipp BG, Baruch DI, Brady C, et al. Recombinant PfEMP1 peptide inhibits and reverses cytoadherence of clinical Plasmodium falciparum isolates in vivo. Blood 2003; 101:331-7.
14. Bull HA, Brickell PM, Dowd PM. Src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells. FEBS Lett 1994; 351: 41-4.
15. Yipp BG, Robbins SM, Resek ME, Baruch DI, Looareesuwan S, Ho M. Src-family kinase signaling modulates the adhesion of Plasmodium falciparum on human microvascular endothelium under flow. Blood 2003; 101:2850-7.
16. Anagnostou F, Plas C, Forest N. Ecto-alkaline phosphatase considered as levamisole-sensitive phosphohydrolase at physiological pH range during mineralization in cultured fetal calvaria cells. J Cell Biochem 1996; 60:484-94.
17. Dondorp AM, Silamut K, Charunwatthana P, et al. Levamisole inhibits sequestration of infected red blood cells in patients with falciparum malaria. J Infect Dis 2007; 196:460-6.
18. Thein-Hlaing, Than-Saw, Myat-Lay-Kyin. Control of ascariasis through age-targeted chemotherapy: impact of 6-monthly chemotherapeutic regimens. BullWorld Health Organ 1990; 68:747-53.
19. World Health Organization. Roll Back Malaria Department. Guidelines for the treatment of malaria. Geneva, Switzerland: World Health Organization, 2006.
20. Tran TH, Day NP, Nguyen HP, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335:76-83.
21. Chiadmi F, Lyer A, Cisternino S, et al. Stability of levamisole oral solutions prepared from tablets and powder. J Pharm Pharm Sci 2005; 8:322-5.
22. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011; 10:339.
23. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413-22.
24. Dondorp AM, Desakorn V, Pongtavornpinyo W, et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med 2005; 2:e204.
25. Dondorp AM, Ince C, Charunwatthana P, et al. Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis 2008; 197:79-84.
26. Vandamme TF, Demoustier M, Rollmann B. Quantitation of levamisole in plasma using high performance liquid chromatography. Eur J Drug Metab Pharmacokinet 1995; 20:145-9.
27. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58:51-64.
28. Gwilt P, Tempero M, Kremer A, Connolly M, Ding C. Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil. Cancer Chemother Pharmacol 2000; 45:247-51.
29. Udomsangpetch R, Pipitaporn B, Silamut K, et al. Febrile temperatures induce cytoadherence of ring-stage Plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci USA 2002; 99:11825-9.
30. Day NP, Phu NH, Mai NT, et al. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med 2000; 28:1833-40.
31. Davies IP, Veys J. The use of fluorescein in contact lens aftercare. Cont Lens Anterior Eye 2009; 32:187-9.
32. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993; 76:85-95.
33. Krishna S, Waller DW, Ter Kuile F, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 1994; 88:67-73.
34. Luyckx M, Rousseau F, Cazin M, et al. Pharmacokinetics of levamisole in healthy subjects and cancer patients. Eur J Drug Metab Pharmacokinet 1982; 7:247-54.
35. Day NP, Phu NH, Bethell DP, et al. The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet 1996; 348:219-23.
36. van Hensbroek MB, Palmer A, Onyiorah E, et al. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis 1996; 174:1091-7.
37. Hemmer CJ, Kern P, Holst FG, Nawroth PP, Dietrich M. Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study. Am J Trop Med Hyg 1991; 45:608-12.
38. Hoffman SL, Rustama D, Punjabi NH, et al. High-dose dexamethasone in quinine-treated patients with cerebral malaria: a double-blind, placebo-controlled trial. J Infect Dis 1988; 158:325-31.
39. Maitland K, Babiker A, Kiguli S, Molyneux E. The FEAST trial of fluid bolus in African children with severe infection. Lancet 2012; 379:613; author reply 614.
40. Taylor TE, Molyneux ME, Wirima JJ, Borgstein A, Goldring JD, Hommel M. Intravenous immunoglobulin in the treatment of paediatric cerebral malaria. Clin Exp Immunol 1992; 90:357-62.
41. Mohanty D, Ghosh K, Pathare AV, Karnad D. Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria. Indian J Med Res 2002; 115:17-21.
42. Smith HJ, Meremikwu M. Iron chelating agents for treating malaria. Cochrane Database Syst Rev 2003:CD001474.
43. Akech SO, Jemutai J, Timbwa M, et al. Phase II trial on the use of dextran 70 or starch for supportive therapy in Kenyan children with severe malaria. Crit Care Med 2010; 38:1630-6.
44. Okoromah CA, Afolabi BB, Wall EC. Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria. Cochrane Database Syst Rev 2011:CD004615.
45. Mohanty S, Mishra SK, Patnaik R, et al. Brain swelling and mannitol therapy in adult cerebral malaria: a randomized trial. Clin Infect Dis 2011; 53:349-55.
46. Charunwatthana P, Abul Faiz M, Ruangveerayut R, et al. Nacetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial. Crit Care Med 2009; 37:516-22.
47. Meremikwu M, Marson AG. Routine anticonvulsants for treating cerebral malaria. Cochrane Database Syst Rev 2002:CD002152.
48. Treeprasertsuk S, Silachamroon U, Krudsood S, et al. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice. J Gastroenterol Hepatol 2010; 25:362-8.